Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period ending January 31, 2014, covering an event that occurred on January 28, 2014. The filing addresses Item 5.02 regarding the modification of compensatory arrangements for Dr. Karl Johe.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation terms.
Material Changes
The Compensation Committee approved a modification to Dr. Karl Johe's stock option grant originally issued on July 25, 2012. The key changes include:
- Grant Details: 5,000,000 common stock purchase options with an exercise price of $0.92 and a 10-year term.
- Vesting Condition Met: The condition requiring shareholder approval for the final 2,000,000 options was satisfied on June 21, 2013.
- Modification: The Committee removed a provision that would have reduced the number of shares exercisable from the final 2,500,000 options if the stock price exceeded $5.00 on the day of exercise.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the specific equity modification described.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2010 Equity Compensation Plan following the June 2013 amendment.
- Confirm the impact of removing the $5.00 price cap reduction on the company's potential dilution.
- Review the full employment contract of Dr. Karl Johe to understand other vesting conditions.